专利号:US-6642377-B1 优先权日:1999-07-30 标 题 :Process for the preparation of basic antibiotic-inorganic acid addition salts and intermediate oxalates 发明人:KAYANO AKIO; CHIBA HIROYUKI; NAKAMURA TAIJU; SAKURAI SHIN; ISHIZUKA HIROYUKI; SAITO HIROYUKI; KOMATSU YUUKI; SASHO MANABU; SATO NOBUAKI; NEGI SHIGETO 权利人:EISAI CO LTD 摘要:A production process which comprises subjecting a basic antibiotic.oxalate (II) to salt-exchange with an alkali earth metal salt (III) of an inorganic acid:wherein the ring A means the basic antibiotic; R<10 >means a protected functional group used in organic synthesis; Ak-E means the alkali earth metal; and B means the inorganic acid, respectively.
1: Ohtaki K, Matsubara K, Fujimaru S, Shimizu K, Awaya T, Suno M, Chiba K, Hayase N, Shiono H. Cefoselis, a beta-lactam antibiotic, easily penetrates the blood-brain barrier and causes seizure independently by glutamate release. J Neural Transm (Vienna). 2004 Dec;111(12):1523-35. doi: 10.1007/s00702-004-0177-0. Epub 2004 Jul 7. 13(2):e1119. doi: 10.1002/ctm2.1119. 3: Zalewski P, Skibiński R, Talaczyńska A, Paczkowska M, Garbacki P, Cielecka- Piontek J. Stability studies of cefoselis sulfate in the solid state. J Pharm Biomed Anal. 2015 Oct 10;114:222-6. doi: 10.1016/j.jpba.2015.05.033. Epub 2015 Jun 1. 11:180. doi: 10.3389/fmicb.2020.00180.
合成参考文献
参考文献:10.2165/00044011-199815050-00007 摘要:Rossini F, Pioltelli P, Bolis S, Borin L, Casaroli I, Lanzi E, Maffè P, Parma M, Tripputi P, Pogliani EM. Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes. Clin Drug Investig. 1998;15(5):425–33. doi: 10.2165/00044011-199815050-00007. 参考文献:10.1007/s101560200022 摘要:Kumazawa J, Yagisawa M. The history of antibiotics: the Japanese story. J Infect Chemother. 2002 Jun;8(2):125–33. doi: 10.1007/s101560200022. 参考文献:10.1007/s101560200024 摘要:Ida T, Tsushima M, Ishii T, Atsumi K, Tamura A. CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. J Infect Chemother. 2002 Jun;8(2):138–44. doi: 10.1007/s101560200024.